Key figures include Gilead Chairman and CEO Daniel O’Day, who highlighted the deal as a milestone following a two-year collaboration, and Tubulis CEO Dominik Schumacher.[2][4][9] Prior partnerships shaped the path: Gilead's 2024 option/license agreement (up to $465 million) for an undisclosed ADC, Tubulis' 2023 Bristol Myers Squibb alliance, and $600+ million in venture funding including a €344 million Series C in 2025.[4][5][6][8] Tubulis spun out from German research institutes in 2019 to advance ADCs with improved selectivity, reduced toxicity, and novel payloads for resistant tumors.[4][6]
Gilead's aggressive 2026 oncology M&A—following $7.8 billion for Arcellx (February) and $2.2 billion for Ouro Medicines (March)—builds on its $21 billion 2020 Immunomedics buy for Trodelvy, addressing pipeline gaps in high-unmet-need cancers amid booming ADC demand.[5][6][8] Newsworthy for its scale in the hot ADC field (many approvals/developments), validation of Tubulis' tech, and Gilead's oncology push from a "position of strength" post-JPM 2026.[4][6][7]